40 results about "Asthmatic patient" patented technology

The invention relates to the technical field of medical health monitoring and management, and particularly discloses a pediatric asthma patient health management system combined with multistage supervision, which comprises a data acquisition module, a respiratory stability evaluation module, a respiratory mechanics sufficiency evaluation module, an asthma state comprehensive evaluation module and an early warning intervention module, a wearable device is used for collecting airway resistance and elastic retraction force physiological signals of a child patient in real time, an airway reaction differential frequency characteristic value and a respiratory mechanics difference characteristic value are extracted respectively, and comprehensive evaluation is conducted from the two dimensions of respiratory tract dynamic stability and lung recruitment capacity. The feature fusion is further input into an asthma severity judgment model constructed based on a random forest algorithm, intelligent grading of asthma states is achieved, a three-level early warning mechanism is triggered according to a grading result, and remote notification and personalized intervention are supported.

The invention provides a traditional Chinese medicine composition for treating or improving asthma, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials: inula flower, tabasheer, Japanese ardisia herb, cymbopogon distans, ligusticum, pyrrosia lingua, pawpaw, yam rhizome, rhizoma atractylodis, walnut meat, maltose, citron and liquorice. The monarch, minister, assistant and guide in the traditional Chinese medicine composition make the best responsibility, the traditional Chinese medicine composition aims at the symptoms of phlegm-qi obstruction and adverse rising of lung qi of asthma, also has the effects of strengthening the spleen, tonifying the kidney, soothing the liver and the like to consolidate the root cause, has the effects of dispelling wind and ventilating the lung, eliminating phlegm and lowering adverse qi, tonifying the spleen and eliminating dampness, warming the kidney and absorbing qi, and regulating the liver and regulating qi, and has the effects of purgation and tonification and treatment of both symptoms and root causes. The traditional Chinese medicine composition can effectively inhibit airway inflammation reaction of asthma model mice and improve clinical symptoms of the asthma mice, and is remarkable in treatment effect. The traditional Chinese medicine composition disclosed by the invention has a relatively high total effective rate for treating asthma, and has more advantages in the aspects of relieving clinical symptoms of asthma patients and improving lung functions.

Methods for treating patients with moderate-to-severe asthma comprising administering a therapeutically effective amount of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.

The invention discloses a traditional Chinese medicine composition for treating asthma as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine, the traditional Chinese medicine composition comprises the following medicinal raw materials in parts by mass: 5-15 parts of ephedra, 10-30 parts of humulus scandens, 5-20 parts of radix sophorae flavescentis, 5-20 parts of earthworm, 10-30 parts of semen lepidii, 5-20 parts of rhizoma pinellinae praeparata, 3-9 parts of asarum, 10-30 parts of wild buckwheat, 5-20 parts of blackberry lily, 5-25 parts of raw almond, 5-20 parts of mangnolia officinalis and 5-20 parts of schisandra chinensis. The invention further discloses a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine has the beneficial effects that the traditional Chinese medicine treats asthma from dampness, has the core of clearing heat and eliminating phlegm, freeing lung and relieving asthma, and consolidating foundation and clearing damp, can improve the damp syndrome state of asthma patients, relieve clinical symptoms such as wheeze, shortness of breath, chest distress and cough, improve the life quality and improve the asthma control level, and has potential advantages of reducing acute attack of asthma.

The invention provides a traditional Chinese medicine composition for treating or improving asthma, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials: inula flower, tabasheer, Japanese ardisia herb, cymbopogon distans, ligusticum, pyrrosia lingua, pawpaw, yam rhizome, rhizoma atractylodis, walnut meat, maltose, citron and liquorice. The monarch, minister, assistant and guide in the traditional Chinese medicine composition make the best responsibility, the traditional Chinese medicine composition aims at the symptoms of phlegm-qi obstruction and adverse rising of lung qi of asthma, also has the effects of strengthening the spleen, tonifying the kidney, soothing the liver and the like to consolidate the root cause, has the effects of dispelling wind and ventilating the lung, eliminating phlegm and lowering adverse qi, tonifying the spleen and eliminating dampness, warming the kidney and absorbing qi, and regulating the liver and regulating qi, and has the effects of purgation and tonification and treatment of both symptoms and root causes. The traditional Chinese medicine composition can effectively inhibit airway inflammation reaction of asthma model mice and improve clinical symptoms of the asthma mice, and is remarkable in treatment effect. The traditional Chinese medicine composition disclosed by the invention has a relatively high total effective rate for treating asthma, and has more advantages in the aspects of relieving clinical symptoms of asthma patients and improving lung functions.

Methods for increasing forced expiratory volume in one second (FEV1) in a patient with asthma are presented, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.

The invention discloses a preparation method of a pyridopyrimidine compound and application of the pyridopyrimidine compound in preparation of an asthma medicine. The pyridopyrimidine compound provided by the invention is applied to preparation of medicines for preventing / treating asthma, DPPO is applied to prevention and treatment of bronchial asthma, and a new medicine choice is brought to asthma patients. Experimental results show that the DPPO can obviously inhibit attack of asthma and secretion of related inflammatory factors such as IL-1beta, IL-4, IL-5, IL-6, IL-13 and IL-17A, has a relaxation effect on tracheal smooth muscles, has the effects of resisting angiogenesis, airway remodeling and inflammation, and achieves the effect of treating asthma. In addition, current researches show that the asthma pathogenesis is very complex, DPPO can obviously improve pathological changes of mouse lung tissues sensitized by house dust mite extract (HDM) and toluene diisocynate (TDI), and the DPPO has certain universality and can be speculated to have huge application potential in research and development of drugs for treating various asthma.

The biomarker, the analysis method and the application can be effectively used for early diagnosis, disease course monitoring and prognosis evaluation of asthma, are high in sensitivity, rapid, convenient and accurate and reliable in result, can be used for multiple times of monitoring in a clinical control period, a chronic duration period and an acute attack period of an asthma patient, and provide a basis for clinical decision making. Meanwhile, a certain basis is provided for subsequent fundamental research and clinical research, and the method has great application and research values.

The invention provides a wearable wireless stethoscope early warning device for monitoring acute attack of an asthma patient, the wearable wireless stethoscope early warning device comprises a vest, a first binding belt and a second binding belt, the first binding belt and the second binding belt are arranged on two sides of the vest, two adjusting belts are arranged above the vest, and the two adjusting belts are connected with the vest; a miniature sound signal sensor, a miniature lung sound discriminator and a signal microprocessor are arranged in the vest, the miniature sound signal sensor is used for collecting breathing sound signals, and the miniature lung sound discriminator is used for recognizing dry rale, wet rale and normal breathing sound. The breathing sound of an asthma patient, especially a child patient, is monitored in real time, abnormal breathing sound characteristics are accurately recognized, timely early warning of acute attack is achieved, by means of wireless transmission and a remote diagnosis technology, a doctor can remotely obtain illness state information of the patient, timely diagnosis and treatment guidance is provided for the patient, and the patient experience is improved. The risk caused by acute attack of asthma is reduced, and the health management level of patients is improved.

Identifying and refining clinically significant patient stratification is a critical step toward realizing the promise of precision medicine in a number of medical conditions such as asthma. In this context, we describe the construction unbiased patient stratification scores based on DNA methylation (DNAm) patterns and gene expression patterns and their utilization to refine the efficacy of hallmark biomarkers for predicting drug response in asthma patients, as well as patients having diseases / conditions caused by excessive Type 2 inflammation, such as atopic dermatitis.

The invention discloses an application of ALDH7A1 protein in preparation of a kit for diagnosing asthma. The invention finds that (1) the ALDH7A1 protein content is negatively correlated with the absolute value and IgE content of serum eosinophils serving as typical characteristics of asthma patients and has significance; 2) the area AUC under an ROC curve for diagnosing and distinguishing an asthma patient and a healthy subject by the ALDH7A1 protein drawn in a training set sample is up to 0.907, which shows that the diagnosis has higher accuracy; and 3) the parameters obtained by training of the training set are used as diagnosis thresholds to predict samples in the verification set, the prediction accuracy is nearly 80%, and the accuracy is high. Therefore, the ALDH7A1 protein has high accuracy in diagnosing and distinguishing healthy subjects and asthma patients, and has the prospect of being developed into a kit for diagnosing asthma.

The invention discloses a bronchial asthma treatment drug based on RBX1 inhibition and application thereof, and finds that expression of RBX1 in asthma patients and disease models is up-regulated, and the expression level of RBX1 is in positive correlation with airway epithelial barrier injury and active oxygen accumulation degree, which indicates that RBX1 is a key new target for asthma treatment. On the basis of the compound Z226407860 and the compound Z4189742053, the condition that the expression of the RBX1 can be effectively inhibited is further proved. In an in-vitro model, the compounds not only significantly reduce the protein level of RBX1, but also show a good synergistic treatment effect: the compounds can effectively relieve the injury of the airway epithelial barrier and promote the integrity recovery of the barrier, and can inhibit the excessive accumulation of active oxygen at the same time, so that the asthma process is intervened from two correlative core pathological links. The research provides a solid experimental basis and a candidate compound with a clear prospect for developing a therapeutic drug which aims at bronchial asthma and has a brand new action mechanism.

The present invention provides therapeutic agents for treating human asthma through administration of an IL-6 inhibitor to humans. Representative IL-6 inhibitors in the present invention include IL-6 receptor antibodies and IL-6 antibodies. Therapeutic agents of the present invention can yield therapeutic effects in severe asthma patients who need administration of high-dose steroids and such for alleviation of symptoms, or even in patients whose symptoms are difficult to control by common treatment.

A healthcare device for asthmatic patients that can help in reducing and avoiding risk factors that can trigger one or more symptoms of asthma. The healthcare device includes an infrared sensor, a pulse oximeter sensor, a UV sensor, an atmospheric sensor, and an air quality sensor for measuring values of different risk factors including ambient temperature, body temperature, blood oxygen saturation level, heart rate, intensity of ultraviolet radiations, humidity level, altitude, CO2 levels, and total volatile organic compounds (TVOCs).

The invention discloses an expiratory gas metabolite combined marker for diagnosing asthma and a screening method of the expiratory gas metabolite combined marker. The expiratory gas metabolite combined marker for diagnosing asthma consists of dimethylamine and amino styrene. The screening method comprises the following steps: respectively collecting an exhaled gas sample of a healthy person and an exhaled gas sample of an asthma patient; carrying out HPPI-TOFMS detection analysis on the exhaled gas sample to obtain an original fingerprint spectrogram of the metabolic components; the spectrogram data is preprocessed, the obtained data containing metabolite information is sequentially subjected to univariate analysis and multivariate analysis, differential metabolites between the healthy people and the asthma patients are screened out, and the optimal combination of the differential metabolites between the healthy people and the asthma patients is screened out through binary logistic regression analysis, namely the combined marker; the HPPI-TOFMS analysis technology and the metabonomics method are combined to be used for screening the expired gas metabolite combined marker of bronchial asthma for the first time, and the method is easy to operate and has important economic benefits and wide application prospects.

To provide methods of increasing forced expiratory volume in one second (FEV1) in an asthma patient.SOLUTION: A method comprises subcutaneously administering an effective amount of benralizumab or an antigen-binding fragment thereof, which is about 2 mg to about 100 mg per dose every 4-12 weeks, where the patient uses a high-dose inhaled corticosteroid (ICS) or long-acting β2 agonist (LABA).SELECTED DRAWING: None

The present application belongs to the technical field of biological medicine, and particularly relates to a pyruvate preparation for asthma treatment and a preparation method thereof. The pyruvate preparation comprises the following components in parts by weight: 10-12 parts of pyruvate, 10-12 parts of sodium chloride, 0.5-1 part of citric acid, and 500 parts of water for injection; and the pH of the pyruvate preparation is 6-7. The pyruvate preparation is used for daily management of asthma patients, can control the increase of inflammatory cells such as eosinophilic granulocyte, reduce inflammatory reaction, and thus achieve the purpose of inhibiting asthma. The effect of the pyruvate preparation is close to that of the same kind of hormone drug dexamethasone, and the pyruvate preparation can achieve the treatment purpose while reducing the dependence of patients on hormone drugs and side effects.

This invention provides a traditional Chinese medicine composition for treating or improving asthma, relating to the field of traditional Chinese medicine pharmaceutical technology. The composition comprises the following raw materials: Inula japonica, Bambusa textilis, Lysimachia christinae, Rutaecarpa, Ligusticum striatum, Pyrrosia lingua, Chaenomeles speciosa, Dioscorea hypoglauca, Atractylodes lancea, walnut kernel, maltose, Citronella arvense, and Glycyrrhiza uralensis. In this invention, each ingredient in the composition fulfills its specific function, addressing both the symptoms of asthma (phlegm and qi stagnation, and upward flow of lung qi) and the underlying causes (spleen strengthening, kidney tonification, and liver soothing). This achieves the combined effects of dispelling wind and clearing the lungs, resolving phlegm and descending rebellious qi, strengthening the spleen and resolving dampness, warming the kidneys and promoting qi circulation, and regulating liver qi. It treats both the symptoms and the root cause. This invention's composition effectively inhibits airway inflammation in asthma model mice, improves clinical symptoms, and demonstrates significant therapeutic effects. The composition exhibits a high overall effective rate in treating asthma, with particular advantages in alleviating clinical symptoms and improving lung function in asthma patients.

The invention discloses an asthma management system combined with air quality analysis, and belongs to the technical field of asthma management systems, and the system comprises a personalized health record module which is used for collecting and storing the medical information of each patient, and obtaining the medical information of each patient through a machine learning algorithm; the personalized health archive module can establish a personalized health archive for each patient according to the collected medical information and is used for providing a basis for subsequent decision making, and the real-time air quality monitoring module is used for being connected with an external air quality monitor, collecting and analyzing pollutant information in air in real time and providing a real-time air quality monitoring result. The real-time air quality monitoring module can convert collected pollutant information into indexes having practical significance for asthma patients. The problems that an existing asthma management system is complex in operation, long in data processing and analysis process and inscriptional in system decision making are solved.

The present invention refers to the medical field. Particularly, the present invention refers to an in vitro method for the diagnosis of allergic asthma or nonallergic asthma in a subject suffering from asthma, or for the differential diagnosis of allergic asthma and nonallergic asthma in a subject suffering from asthma, or for the prognosis of asthma in a subject suffering from asthma, which comprises assessing the expression level of the LGALS3 gene in a biological sample obtained from the subject. It also refers to the in vitro use of the expression level of the LGALS3 gene, or in vitro use of a kit comprising reagents for the same purposes.

The invention belongs to the technical field of biological medicines, and relates to application of an interleukin 33 antibody in preparation of a medicine for relieving asthma aggravation, in particular to application of the interleukin 33 antibody in preparation of a medicine for relieving asthma aggravation induced by ozone exposure. According to the application disclosed by the invention, comprehensive research experiments are adopted, the intervention treatment of the IL-33 antibody is implemented by constructing an asthma model and utilizing an ozone-induced asthma exacerbation model, and the pathophysiological action of the IL-33 antibody in relieving ozone-induced asthma exacerbation is comprehensively disclosed. Experimental results show that the IL-33 antibody can relieve the conditions of asthma mouse lung dysfunction, lung tissue inflammatory cell infiltration and immune cell imbalance in lung tissue caused by ozone exposure. The invention provides a new perspective for the treatment of asthma, and provides a scientific basis and practical value for developing a novel and effective asthma prevention and treatment strategy. The traditional Chinese medicine composition is expected to improve the living quality of asthma patients and reduce health risks caused by environmental pollutants, and has important clinical significance and social value.

The invention relates to a preparation method and application of serum exosome miR-98-5p of an asthma patient, and belongs to the technical field of biological medicine and molecular biology. The preparation method of the serum exosome miR-98-5p of the asthma patient comprises the following steps: S1, collecting the serum of the asthma patient, heating to quickly melt a sample, then performing centrifugal treatment, taking supernate, filtering by a filter membrane, and collecting filtrate; s2, the filtrate is subjected to centrifugal treatment, supernate is removed, and an exosome crude extract is obtained; s3, the exosome crude extract is subjected to centrifugal treatment after being resuspended, supernate is removed, resuspension is conducted, and the serum exosome of the asthma patient is obtained. According to the present invention, BEAS-2B cells are treated by using the serum exosome of an asthma patient, a miR-22-3p mediated TGF-beta / SMAD pathway is down-regulated to participate in cell epithelial-mesenchymal transition, and proliferation and migration of lung epithelial cells BEAS-2B are promoted;

The invention discloses application of human metapneumovirus in preparation of a medicine for treating asthma, and belongs to the technical field of asthma medicines. The human metapneumovirus is used in the medicine for treating asthma, can relieve airway hyperresponsiveness of an asthma patient, reduce expression of MUC5AC, IL-4 and p-STAT6 proteins of the asthma patient, reduce the total cell number, eosinophilic granulocyte number and neutrophil number in BALF, and can effectively treat asthma and relieve asthma symptoms.

The invention relates to the technical field of aerosol inhalation equipment, in particular to a targeted aerosol inhalation administration device for acute lung injury, which comprises an atomizer, a communicating pipe, a preheating mechanism and an atomizing mechanism, a preheating mechanism is installed above the atomizer, a communicating pipe is arranged in the preheating mechanism, one end of the communicating pipe communicates with the atomizer, and the other end of the communicating pipe communicates with an atomizing mechanism; the preheating mechanism comprises a heating frame fixedly connected with the atomizer, a bottom plate is arranged in the heating frame, a plurality of guide grooves are formed in the bottom plate, springs are arranged in the guide grooves, one end of each spring is fixedly connected with a moving column, and the other end of each spring is fixedly connected with the inner wall of the heating frame; the communicating pipe is preheated, so that the airflow temperature is appropriate, cold fog is prevented from stimulating the airway, uncomfortable symptoms such as cough and bronchus spasm are reduced, and the use tolerance of children, old people, chronic obstructive pulmonary disease patients and asthma patients is improved.

The invention discloses application of an LXR agonist in preparation of a medicine for preventing, treating and / or relieving asthma. The invention discovers that the LXR agonist GW3965 can restore the sensitivity of asthma to hormone therapy by adjusting the polarization state of macrophages, so that the airway inflammation and airway remodeling reaction of a T2-low asthma patient are remarkably improved, and the asthma is further prevented, treated or relieved. The LXR agonist treatment method has remarkable clinical significance for patients with the glucocorticoid-resistant T2-low asthma, can be widely used for treating the T2-low asthma, especially for high-risk groups with the glucocorticoid resistance, and provides a new thought and a new target for clinically developing novel drugs for treating the asthma in the future.

The invention discloses a pharmaceutical composition for preventing or treating asthma diseases, the pharmaceutical composition comprises a bronchiectasis agent and glucocorticoid, the bronchiectasis agent is preferably formoterol and pharmaceutically acceptable salts thereof or solvates thereof or solvates of the salts, and the glucocorticoid is preferably fluticasone furoate. The pharmaceutical composition provided by the invention can more safely and effectively delay the next attack time of an acute asthma patient.

This disclosure provides a peripheral blood plasma biomarker for detecting asthma patients, belonging to the field of biotechnology. The peripheral blood plasma biomarker for detecting asthma patients includes miR-129-2-3p. miR-129-2-3p can serve as a target for the diagnosis and treatment of asthma.

A method for determining a risk of triggering a respiratory disorder compared to a general patient population is disclosed. Data is collected about activations of a medication device for delivering a respiratory medication to a patient population. The activation data and patient context parameter data associated with each activation event are stored. A data analysis module determines the occurrence of rescue events based on the collected activation data and determines a coefficient of the context parameter as a trigger event for a primary patient based on a correlation between the context parameter and the rescue event. The data analysis module provides a comparison of a coefficient of at least one context parameter for the primary patient to a coefficient distribution of trigger events for the patient population based on the correlation between the context parameter and the rescue event for the patient population.

The invention discloses a novel compound traditional Chinese medicine asthma-relieving aerosol which is prepared from the following raw materials in parts by weight: 10-60 parts of agastache rugosus, 10-60 parts of pericarpium citri reticulatae, 10-60 parts of mangnolia officinalis and 10-60 parts of perilla leaves. The invention further discloses a preparation method of the novel compound traditional Chinese medicine asthma-relieving aerosol. The invention provides an efficient and safe traditional Chinese medicine asthma-relieving aerosol capable of treating acute attack of asthma and a preparation method thereof, the aerosol is convenient to dose, can be inhaled through atomization, is convenient to use, has a unique treatment effect, can effectively prevent and treat asthma patients after being continuously used twice a day for 5-7 days, treats both symptoms and root causes, and is short in treatment period, quick in effect taking, reliable in effect and free of toxic and side effects. The traditional Chinese medicine composition has the effects of spasmolysis, anti-inflammation, anti-allergic reaction and the like.

The present invention relates to a composition for co-administering Belzutifan, which is an HIF-2ɑ activity inhibitor having a steroid-resistant allergic airway inflammation reduction effect, and a steroid. The composition according to the present invention has the effect of alleviating inflammation and symptoms by co-administering an HIF-2ɑ inhibitor during the treatment of severe allergic asthma patients exhibiting steroid resistance. Thus, co-administering Belzutifan, which is an HIF-2ɑ inhibitor, and a steroid is a more effective treatment that can alleviate asthma and increase the quality of life of severe asthma patients.